ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2025
The relationship between the dynamic trajectory of inflammatory markers in VA-ECMO patients and the 28-day survival rate, as well as mediating causal analysis.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical outcomes of VA-ECMO in children with fulminant myocarditis: a single-centre case series.BMC pediatrics · 2026Article
- Systematic review, meta-analysis, and meta-regression of the association of serial leukocyte counts in critically ill patients and mortality.Annals of intensive care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVeno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a simplified cardiopulmonary bypass device that provides temporary respiratory and circulatory support and adequate recovery time for the heart and lung, but the mortality rate of acute and critically ill patients undergoing VA-ECMO is still high. Progression of systemic inflammatory response is associated with mortality in ECMO patients. The objective of this study was to investigate the dynamic changes of various inflammatory markers and their relationship with 28-day mortality in patients with VA-ECMO.
methodsA retrospective cohort analysis was conducted on 200 patients receiving VA-ECMO treatment evaluating inflammatory markers including neutrophil-to-lymphocyte ratio (NLR), systemic inflammatory response index (SIRI), procalcitonin (PCT), interleukin-6 (IL-6), and C-reactive protein (CRP) at various time points. A dynamic trajectory model was constructed, and survival differences between groups were assessed using Kaplan-Meier plots and log-rank tests. Multiple Cox proportional hazard models were built to analyze the relationship between dynamic trajectories and clinical outcomes. Causal mediation analysis was applied to determine whether changes in inflammatory trajectories mediated survival outcomes in patients on VA-ECMO through other variables.
resultsAge, Acute Physiology and Chronic Health Evaluation (APACHE) II score, Lactic acid, PCO2, aspartate aminotransferase (AST) levels, diastolic blood pressure, mean arterial pressure and pH significantly impacted the 28-day survival rate (p < 0.05), with higher mortality observed in patients exhibiting poor inflammatory trajectories.Kaplan-Meier survival analysis revealed that patients in the ascending (AS) group had a significantly higher risk of death than those in the stable (ST) and descending (DS) groups (log-rank p < 0.001). Furthermore, multivariate Cox regression analysis identified IL-6 as the most strongly correlated inflammatory marker with mortality risk [Hazard ratio (HR) = 1.97, 95% confidence interval (CI) 1.35-2.87, p < 0.001].
conclusionsThis study highlights the importance of dynamic monitoring of inflammatory biomarkers in patients on VA-ECMO, suggesting that individualized treatment adjustments based on these markers could enhance survival rates. Future research should prioritize larger, multicenter cohort studies and clinical trials to validate these findings, aiming to optimize treatment strategies for patients on VA-ECMO.
Indexed as
Identifiers
40038134What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.